Content about Ranbaxy Labs

May 9, 2013

The November 2011 expiration of Pfizer's patent on the cholesterol drug Lipitor and Ranbaxy Labs' release of the generic version received significant play in the media, particularly due to the theretofore status of Lipitor (atorvastatin calcium) as the drug with the highest sales in the country, $7.7 billion in the United States, according to healthcare analytics firm IMS Health.

The November 2011 expiration of Pfizer's patent on the cholesterol drug Lipitor and Ranbaxy Labs' release of the generic version received significant play in the media, particularly due to the theretofore status of Lipitor (atorvastatin calcium) as the drug with the highest sales in the country, $7.7 billion in the United States, according to healthcare analytics firm IMS Health.

March 5, 2013

Ranbaxy Labs will market a drug for depression under an agreement with another company, the drug maker said Tuesday.

PRINCETON, N.J. — Ranbaxy Labs will market a drug for depression under an agreement with another company, the drug maker said Tuesday.

Ranbaxy said it had entered an in-licensing agreement with Alembic Pharmaceuticals to market desvenlafaxine base extended-release tablets. Alembic is the sponsor of a new drug application filed with the Food and Drug Administration for the drug, which is bioequivalent to Pfizer's Pristiq. Pristiq had sales of $590 million during the 12-month period that ended in January.

February 26, 2013

Drug maker Ranbaxy Labs has started producing the ingredients for a cholesterol drug while working with the Food and Drug Administration to fix manufacturing issues that led to the recall in November 2012 of several batches of the drug.

NEW YORK — Drug maker Ranbaxy Labs has started producing the ingredients for a cholesterol drug while working with the Food and Drug Administration to fix manufacturing issues that led to the recall in November 2012 of several batches of the drug.

The Indian drug maker said it had initiated corrective and preventive actions, or CAPA, as it prepared to resume supplies of generic atorvastatin calcium tablets to the U.S. market. The drug is a generic version of Pfizer's Lipitor, and Ranbaxy became the first company to market a generic version in November 2011.

January 3, 2013

A court has ruled in favor of Indian generic drug maker Ranbaxy Labs in a case concerning a generic blood pressure drug, the legal firm representing the drug maker said.

WASHINGTON — A court has ruled in favor of Indian generic drug maker Ranbaxy Labs in a case concerning a generic blood pressure drug, the legal firm representing the drug maker said.

Zuckerman Spaeder LLP said the U.S. District Court for the District of Columbia upheld a Food and Drug Administration decision protecting Ranbaxy's market exclusivity for a generic version of Novartis' drug Diovan (valsartan).

November 27, 2012

Ranbaxy Labs has recalled more than three dozen lots of its generic version of a cholesterol-lowering statin drug due to the possible presence of foreign particles, the company said.

NEW YORK — Ranbaxy Labs has recalled more than three dozen lots of its generic version of a cholesterol-lowering statin drug due to the possible presence of foreign particles, the company said.

November 26, 2012

Ranbaxy Labs has launched a new treatment for acne under a licensing agreement with a Canadian drug maker.

PRINCETON, N.J. — Ranbaxy Labs has launched a new treatment for acne under a licensing agreement with a Canadian drug maker.

Ranbaxy announced Monday the launch of Absorbica (isotretinoin) capsules for treating severe recalcitrant nodular acne in patients ages 12 years and older. The drug was launched under a license from Mississauga, Ontario-based Cipher Pharmaceuticals.

Normally, oral isotretinoin must be taken with a high-fat meal due to its chemical properties, but Absorbica is designed to be taken without food.

November 15, 2012

The year 2012 is coming to an end, and it’s been a big year for 
generic drugs.


The year 2012 is coming to an end, and it’s been a big year for 
generic drugs.


October 9, 2012

Ranbaxy Labs has launched an authorized generic drug for treating dry mouth associated with an autoimmune disorder, the company said Tuesday.

PRINCETON, N.J. — Ranbaxy Labs has launched an authorized generic drug for treating dry mouth associated with an autoimmune disorder, the company said Tuesday.

The India-based generic drug maker announced the launch of cevimeline hydrochloride in the 30-mg strength under an agreement with parent company Daiichi Sankyo. The drug is used in patients with Sjogren's syndrome, which affects the moisture-producing glands.

August 17, 2012

Ranbaxy Labs has launched an authorized generic version of a diabetes drug made by Takeda Pharmaceutical, Ranbaxy said Friday.

PRINCETON, N.J. — Ranbaxy Labs has launched an authorized generic version of a diabetes drug made by Takeda Pharmaceutical, Ranbaxy said Friday.

Ranbaxy announced the launch, through subsidiary Ranbaxy Pharmaceuticals and under an agreement with Takeda, of pioglitazone hydrochloride tablets, an authorized generic version of Takeda's Actos. An authorized generic is a branded drug marketed at a reduced price under its generic name, typically by a third-party company operating under contract with the original branded drug's manufacturer.

August 14, 2012

Consolidated sales for generic drug maker Ranbaxy Labs totaled $588 million in the second quarter ended June 30, a 28% rise over the year-ago period, the company said.

GURGAON, India — Consolidated sales for generic drug maker Ranbaxy Labs totaled $588 million in the second quarter ended June 30, a 28% rise over the year-ago period, the company said.

The drug maker reported that North American sales soared 140% over the year-ago period to a total of $272 million, aided by strong base business. U.S. sales for Ranbaxy were $255 million for the quarter, thanks to strong base business and exclusivity sales of such drugs as atorvastatin and atorvastatin and amlodipine (Lipitor and Caduet, respectively).

July 10, 2012

India-based drug maker Ranbaxy Labs is looking to expand sales in the U.S. market, according to published reports.

PLAINSBORO TOWNSHIP, N.J. — India-based drug maker Ranbaxy Labs is looking to expand sales in the U.S. market, according to published reports.

The Associated Press said Ranbaxy CEO Arun Sawhney announced his intentions to position the company where it will be first (or one of the first) on U.S. market with just-approved generic drugs, and also is working to expand generic sales in emerging markets, such as India, China, Brazil and Russia. "The U.S., as a total business, will remain the most important to us," Sawhney was quoted as saying.

June 21, 2012

The Food and Drug Administration has approved a branded acne drug made by Ranbaxy Labs, the drug maker said. Ranbaxy announced the FDA approval of Absorica (isotretinoin), a drug for treating severe recalcitrant nodular acne.

The Food and Drug Administration has approved a branded acne drug made by Ranbaxy Labs, the drug maker said. Ranbaxy announced the FDA approval of Absorica (isotretinoin), a drug for treating severe recalcitrant nodular acne. The company expects to launch it in the United States in fourth quarter 2012 under an agreement with Canada-based Cipher Pharmaceuticals.


May 30, 2012

The Food and Drug Administration has approved a branded acne drug made by Ranbaxy Labs, the drug maker said.

PRINCETON, N.J. — The Food and Drug Administration has approved a branded acne drug made by Ranbaxy Labs, the drug maker said.

Ranbaxy announced the FDA approval of Absorica (isotretinoin), a drug for treating severe recalcitrant nodular acne. The company expects to launch Absorica in the United States in fourth quarter 2012 under an agreement with Canada-based Cipher Pharmaceuticals.

May 15, 2012

First-quarter consolidated sales for generic drug maker Ranbaxy Labs totaled $736 million, the company reported last week.

GURGAON, India — First-quarter consolidated sales for generic drug maker Ranbaxy Labs totaled $736 million, the company reported last week.

The company said the quarter's sales marked a 55% increase over the year-ago period, when sales totaled $474 million. U.S. sales for the company totaled $416 million, up from $170 million in first quarter 2011. Ranbaxy attributed its sales boost to the launch of generic Lipitor (atorvastatin), as well as sales of generic Caduet (amlodipine and atorvastatin).

May 15, 2012

Pfizer apparently is relenting on its attempt to drive sales of its top cholesterol drug as several new generic versions look set to enter the market, according to published reports.

NEW YORK — Pfizer apparently is relenting on its attempt to drive sales of its top cholesterol drug as several new generic versions look set to enter the market, according to published reports.

The Associated Press reported that Pfizer was "quietly" giving up on the drug Lipitor (atorvastatin) after an $87 million campaign to continue marketing the drug despite generic competition.

April 11, 2012

Move over, Lipitor: There's a new top drug on the market, according to published reports.

NEW YORK — Move over, Lipitor: There's a new top drug on the market, according to published reports.

January 20, 2012

One analysis report after another seems to confirm that the generic drug market is in for a huge shift as the number of blockbuster drugs losing patent protection is set to dwindle over the next several years. A recent report by Frost & Sullivan seems to confirm that sentiment.

WHAT IT MEANS AND WHY IT'S IMPORTANT — One analysis report after another seems to confirm that the generic drug market is in for a huge shift as the number of blockbuster drugs losing patent protection is set to dwindle over the next several years. A recent report by Frost & Sullivan seems to confirm that sentiment.

January 20, 2012

In the Feb. 7, 2011, issue, Drug Store News named three major issues that would define 2011 for the world of generic drugs. Those issues were drug safety, generic user fees and patent settlements.

In the Feb. 7, 2011, issue, Drug Store News named three major issues that would define 2011 for the world of generic drugs. Those issues were drug safety, generic user fees and patent settlements.

January 3, 2012

Pharmacy technology provider PDX is partnering with Mscripts to allow existing PDX Classic and Enterprise Pharmacy System customers to add mobile to their customer-facing offerings, the companies said.

SUPPLIER NEWS — Pharmacy technology provider PDX is partnering with Mscripts to allow existing PDX Classic and Enterprise Pharmacy System customers to add mobile to their customer-facing offerings, the companies said. The features will give pharmacies an outreach channel to improve their bin management and will-call services, as well as allow them to easily identify aging prescriptions and use the Mscripts mobile application to remind customers to pick up their prescriptions.


December 21, 2011

Ranbaxy Labs said Wednesday that it had resolved long-standing issues concerning two of its manufacturing plants in India with the U.S. government.

GURGAON, India — Ranbaxy Labs said Wednesday that it had resolved long-standing issues concerning two of its manufacturing plants in India with the U.S. government.

December 6, 2011

Days after its launch of a generic version of Pfizer's cholesterol-lowering drug Lipitor, Ranbaxy Labs has launched a related drug as an authorized generic.

PRINCETON, N.J. — Days after its launch of a generic version of Pfizer's cholesterol-lowering drug Lipitor, Ranbaxy Labs has launched a related drug as an authorized generic.

Ranbaxy announced the launch of an authorized generic version of Caduet (atorvastatin and amlodipine besylate). The drug is used to treat patients with high blood pressure and high cholesterol. Mylan launched a generic version of the drug on Thursday.

December 5, 2011

With annual sales gaining on the $8 billion mark in the United States alone, according to IMS Health, Lipitor (atorvastatin) is the top-selling drug in the world, and the price markdown that Ranbaxy Labs’ launch (and subsequent generic launches) will bring, greatly will expand its accessibility. So it’s no surprise that it has attracted so much media attention over the past few weeks.

WHAT IT MEANS AND WHY IT'S IMPORTANT — With annual sales gaining on the $8 billion mark in the United States alone, according to IMS Health, Lipitor (atorvastatin) is the top-selling drug in the world, and the price markdown that Ranbaxy Labs’ launch (and subsequent generic launches) will bring, greatly will expand its accessibility. So it’s no surprise that it has attracted so much media attention over the past few weeks.

December 1, 2011

Ranbaxy Labs got the green light from the Food and Drug Administration Wednesday night to launch its generic version of Pfizer's cholesterol-lowering drug Lipitor.

SILVER SPRING, Md. — Ranbaxy Labs got the green light from the Food and Drug Administration Wednesday night to launch its generic version of Pfizer's cholesterol-lowering drug Lipitor.

The FDA announced the approval of Ranbaxy's atorvastatin calcium tablets in the 10-mg, 20-mg, 40-mg and 80-mg strengths. New Brunswick, N.J.-based Ohm Labs will manufacture the drug.

December 1, 2011

Pfizer's efforts to protect the sales of its blockbuster cholesterol drug Lipitor have attracted scrutiny from members of Congress, according to published reports.

NEW YORK — Pfizer's efforts to protect the sales of its blockbuster cholesterol drug Lipitor have attracted scrutiny from members of Congress, according to published reports.

The New York Times reported Thursday that three senators — Max Baucus, D-Mont.; Chuck Grassley, R-Iowa; and Herb Kohl, D-Wis. — had asked Pfizer and five other companies to provide details of their agreements to prevent dispensing of generic versions of Lipitor (atorvastatin) and dispense only the branded version.

November 30, 2011

Ranbaxy Labs was supposed to launch its generic version of the world's top-selling drug Wednesday, but a competitor beat it to the punch as the former waits for final Food and Drug Administration clearance.

NEW YORK — Ranbaxy Labs was supposed to launch its generic version of the world's top-selling drug Wednesday, but a competitor beat it to the punch as the former waits for final Food and Drug Administration clearance.